Juan Eduardo Montero-Hernández

Mr. Juan Eduardo Montero-Hernández

Université de Paris, Centre de Recherche sur l’inflammation, Inserm UMR1149 ; CNRS ERL8252 ; Faculté de Médecine site Bichat, 16 rue Henri Huchard, F-75018 Paris, France
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2022 in Medical Principles and Practice
Verified
Journal Article
Open access
VJVitte Joana
Vitte Joana
SVShamila Vibhushan
Shamila Vibhushan
MBManuela Bratti
Manuela Bratti
Juan Eduardo Montero-HernándezJuan Eduardo Montero-Hernández
Juan Eduardo Montero-Hernández
UBUlrich Blank
Ulrich Blank
IgE-mediated type I hypersensitivity reactions have many reported beneficial functions in immune defense against parasites, venoms, toxins, etc. However, they are best known for their role in allergies, currently affecting almost one third of the population worldwide. IgE-mediated allergic diseases result from a maladaptive type 2 immune response that promotes the synthesis of IgE antibodies directed at a special class of antigens called allergens. IgE antibodies bind to type I high-affinity IgE receptors (FcεRI) on mast cells and basophils, sensitizing them to get triggered in a subsequent encounter with the cognate allergen. This promotes the release of a large variety of inflammatory mediators including histamine responsible for the symptoms of immediate hypersensitivity. The development of type 2-driven allergies is dependent on a complex interplay of genetic and environmental factors at barrier surfaces including the host microbiome that builds up during early life. While IgE-mediated immediate hypersensitivity reactions are undoubtedly at the origin of the majority of allergies, it has become clear that similar responses and symptoms can be triggered by other types of adaptive immune responses mediated via IgG or complement involving other immune cells and mediators. Likewise, various nonadaptive innate triggers via receptors expressed on mast cells have been found to either directly launch a hypersensitivity reaction and/or to amplify existing IgE-mediated responses. This review summarizes recent findings on both IgE-dependent and IgE-independent mechanisms in the development of allergic hypersensitivities and provides an update on the diagnosis of allergy.
1

Verified
Journal Article
Open access
PDF file
SVShamila Vibhushan
Shamila Vibhushan
MBManuela Bratti
Manuela Bratti
Juan Eduardo Montero-HernándezJuan Eduardo Montero-Hernández
Juan Eduardo Montero-Hernández
AGAlaa El Ghoneimi
Alaa El Ghoneimi
MBMarc Benhamou
Marc Benhamou
UBUlrich Blank
Ulrich Blank
A sizable part (~2%) of the human genome encodes for proteases. They are involved in many physiological processes, such as development, reproduction and inflammation, but also play a role in pathology. Mast cells (MC) contain a variety of MC specific proteases, the expression of which may differ between various MC subtypes. Amongst these proteases, chymase represents up to 25% of the total proteins in the MC and is released from cytoplasmic granules upon activation. Once secreted, it cleaves the targets in the local tissue environment, but may also act in lymph nodes infiltrated by MC, or systemically, when reaching the circulation during an inflammatory response. MC have been recognized as important components in the development of kidney disease. Based on this observation, MC chymase has gained interest following the discovery that it contributes to the angiotensin-converting enzyme’s independent generation of angiotensin II, an important inflammatory mediator in the development of kidney disease. Hence, progress regarding its role has been made based on studies using inhibitors but also on mice deficient in MC protease 4 (mMCP-4), the functional murine counterpart of human chymase. In this review, we discuss the role and actions of chymase in kidney disease. While initially believed to contribute to pathogenesis, the accumulated data favor a more subtle view, indicating that chymase may also have beneficial actions.

17 October 2025 in Science Advances
Verified
Journal Article
Open access
PDPierre Duquesne
Pierre Duquesne
CACéline Aoun
Céline Aoun
MKMathieu Kurowska
Mathieu Kurowska
BPBrieuc P. Perot
Brieuc P. Perot
KZKerui Zhang
Kerui Zhang
GMGaël Ménasché
Gaël Ménasché
Dendritic cells (DCs) are professional antigen (Ag)–presenting cells that excel in initiating adaptive immune responses by continuously scanning peripheral tissues for Ags. To facilitate efficient DC migration, constant cross-talk between actin and microtubules is required to coordinate cytoskeletal networks and actomyosin contractility, but the related mechanisms have not been extensively characterized. We show that mouse DCs lacking Kif5b (the heavy chain of kinesin-1) exhibit a major impairment in cell migration in vivo and in vitro. Mechanistically, kinesin-1 coordinates cytoskeletal cross-talk between actin and microtubules during DC migration by modulating negatively RhoA activity through its interaction with GEF-H1, thereby limiting GEF-H1’s availability in the cytosol. The same mechanism operates in human primary monocyte–derived DCs and regulates efficient migration in a confined environment. Thus, our results highlight kinesin-1 as a key regulator of DC migration, through its coordinated control of cytoskeletal dynamics.

7 April 2026
Verified
Thesis
Closed access
Juan Eduardo Montero-HernándezJuan Eduardo Montero-Hernández
Juan Eduardo Montero-Hernández
Analyse du trafic vésiculaire et de la sécrétion de la chimiokine CCL2 dans les mastocytes après activation par le FceRI: Dans ce travail de thèse j'ai étudié le trafic vésiculaire conduisant à la sécrétion de la chimiokine CCL2 et d'une protéine de fusion CCL2-eGFP dans des mastocytes (MC) dérivés de progéniteurs de moelle osseuse ou de cellules péritonéales de souris de type sauvage (WT) ou transgéniques CCL2-eGFP, stimulés par leur récepteur de haute affinité pour l'IgE (Fc'RI). Les MC WT et CCL2-eGFP ont d'abord libéré la chimiokine préstockée, suivie d'une deuxième vague de sécrétion de CCL2 et CCL2-eGFP nouvellement synthétisées avec une cinétique comparable, bien que la protéine de fusion semble être sécrétée moins efficacement. Nos données montrent leur colocalisation partielle avec les endosomes de recyclage VAMP3+ et les endosomes tardifs VAMP7+ suggérant que ces endosomes sont des intermédiaires du trafic vésiculaire du CCL2 sécrété. En accord, la sécrétion de CCL2 est partiellement inhibée dans les MC VAMP7 KO. L'analyse dynamique du trafic vésiculaire de CCL2-eGFP a révélé un mode de sécrétion complexe et diversifié (multidirectionnel, polarisé ou type pseudopode) qui dépend de l'interaction étroite entre les cytosquelettes d'actine et des microtubules. Après sécrétion, la CCL2-eGFP interagit avec les protéoglycanes libérés par dégranulation. Dans une configuration de dégranulation polarisée, la libération précoce de la CCL2-eGFP se fait dans l'interface de dégranulation, et la sécrétion tardive de la CCL2 nouvellement synthétisée montre un trafic multidirectionnel principalement loin de l'interface de dégranulation. In vivo, lors d'une réaction anaphylactique cutanée passive IgE-dépendante, la CCL2 apparait au cours de la première vague de sécrétion dans la circulation alignée sur les vaisseaux probablement en se liant aux protéoglycanes endothéliaux, alors que pendant la deuxième vague la CCL2 sécrétée se retrouve également dans le tissu. Ces deux vagues pourraient jouer un rôle pour attirer au mieux les cellules inflammatoires localement à la fois au niveau vasculaire et tissulaire. Notre étude fournit de nouvelles informations sur la manière dont les MC organisent le site inflammatoire.

12 June 2026 in EMBO Reports
Verified
Journal Article
Open access
ESElena Sindram
Elena Sindram
Juan Eduardo Montero-HernándezJuan Eduardo Montero-Hernández
Juan Eduardo Montero-Hernández
QFQuentin Frenger
Quentin Frenger
HDHannah van Dijk
Hannah van Dijk
ALAnna Lang
Anna Lang
LGLaura Gámez-Díaz
Laura Gámez-Díaz
Patients with lipopolysaccharide-responsive beige-like anchor protein (LRBA) deficiency typically suffer from severe B cell dysfunction. However, the underlying mechanisms remain incompletely understood. In this study, we identify non-muscle myosin IIA (NMIIA) as an interaction partner of LRBA in B cells, and uncover a role for LRBA in regulating actin cytoskeleton dynamics during B cell activation. LRBA-deficient B cells exhibit abnormal migration, impaired F-actin polymerization, and reduced B cell receptor signalling and polarization upon activation. In addition, LRBA deficiency severely disrupts immune synapse formation as evidenced by diminished central SMAC formation, reduced microtubule organizing center translocation and disrupted BCR and lysosome polarization. Consistent with these defects, internalization of the BCR-antigen complex is also impaired. Mechanistically, NMIIA activation, assessed by myosin light chain (MLC) phosphorylation, is reduced in LRBA-deficient cells. In addition, LRBA co-localizes with active NMIIA during both migration and immune synapse formation. Collectively, our findings establish LRBA as an important regulator of cytoskeleton dynamics during B cell activation, which may contribute to the defective humoral immunity observed in LRBA-deficient patients.